Alan M. Ezrin, Ph.D. – Co-Founder, Chief Executive Officer (email@example.com)
Prior to joining NX PharmaGen, Dr. Ezrin served as Director and CEO of Bradmer Pharmaceuticals Inc [TSX: BMR], guiding the company’s transfer of its lead brain cancer drug technology from Duke University and the launch of a landmark Phase III trial with that drug. In his role, Dr. Ezrin served as the primary strategic liaison to the FDA, to key vendors, to investors and equity analysts, and to the pre-eminent physicians in the field. Prior to joining Bradmer, Dr. Ezrin served as a Director and Chief Scientific Officer of Cardiome Pharma Corp. [TSX:COM, NASDAQ:CRME], where he played an integral role in the development of the company’s lead drug candidate from early stage clinical trials through strategic partnership and NDA filing. Dr. Ezrin has more than 27 years of experience in research and business development in both the pharmaceutical and biotechnology sectors in the US and Canada. Dr. Ezrin was with Sterling-Winthrop Research Group from 1982 to 1993, after which he joined Glycomed Inc. as Assistant Vice President of Experimental Therapeutics. In 1995, he joined RedCell Inc. as Vice President of Pre-Clinical Development leading to the restructuring of the firm in 1997 through the creation of ConjuChem Inc. At ConjuChem, Dr. Ezrin served as Chief Operating and Scientific Officer. He joined Cardiome Pharma Corp. in 2001 as its Chief Scientific Officer and played a vital role in the successful evolution of the firm to a leading cardiovascular company listed on the TSX and NASDAQ exchanges. Dr. Ezrin is extensively published in numerous scientific journals and holds numerous patents for inventions in the pharmaceutical industry. In addition, he has raised substantial invested capital and facilitated numerous transactions and partnerships in the biotech sector.
Brian D. Brohman – Co-Founder, Chief Business Officer (firstname.lastname@example.org) .
Prior to joining NX PharmaGen, Mr. Brohman held the position of Chief Financial Officer and/or Chief Business Officer at oncology drug development firms Bradmer Pharmaceuticals Inc. [TSX: BMR] and Aptamera, Inc. (private company). As a co-founder of Bradmer, Mr. Brohman guided all aspects of the company’s business operations from its inception in 2005 through 2009. Activities included the licensing of Bradmer’s technology from Duke University, the raising over $35 million in equity financing, and the negotiation of all major vendor contracts and clinical study agreements with leading cancer centers across the US. While at Aptamera, Mr. Brohman led that company’s fundraising and licensing activities beginning in February 2002 through its successful sale in February 2005 to London-based Antisoma plc. Prior to Aptamera, Mr. Brohman served in a variety of corporate finance and business development roles during an 8-year tenure with Cordis Corp., a multi-billion dollar medical device division of Johnson & Johnson. A graduate of the University of Notre Dame with a BBA in Finance, Mr. Brohman has over 20 years experience in corporate finance and business development, including 16 years in the medical technology field. Since 1995, Mr. Brohman has specialized in the field of business development, and is a veteran of over 100 mergers, acquisitions, licensing and equity financing deals.